TrialHuman vaccines & immunotherapeutics2023

Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.

Gui-Ling Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.